• All about Allergens
  • 250K HP 2017
  • AIFA registered charity
  • AAP Epi update 2017

  • AIFA’s 2018 grant round opens 15 January
    January 10, 2018:  Submissions for AIFA's 2018 grant round open on 15 January and close on 15 March 2018. AIFA supports innovative early stage projects, encourages collaborative research, prioritises early career researchers (working 3-5 years after completion of their PhD) and provides oppor...
  • ASCIA Highlights 2017 and Priorities for 2018
    December 21, 2017:  As we approach the holiday season we would like to take this opportunity to thank ASCIA members, staff and supporters.  Your significant and generous contributions over the past year are greatly appreciated. ASCIA has achieved so much in 2017, as summarised in the “AS...
  • Allergic rhinitis (hay fever) treatment update
    November 30, 2017:  New Clinical Guidelines from the US on allergic rhinitis (hay fever) treatment were published this week (28 November 2017) in the Annals of Internal Medicine http://annals.org/aim The Guidelines were developed by representatives of the American Academy of Allergy, Asthma a...
  • ASCIA website updates: Chlorhexidine allergy (new) and Anaphylaxis guidelines (updated)
    November 28, 2017:  The following 2 ASCIA documents are now available on the ASCIA website - new ASCIA-ANZAAG Chlorhexidine allergy information and updated ASCIA Guidelines for acute management of anaphylaxis for health professionals. New ASCIA-ANZAAG Chlorhexidine (antiseptic agent) allergy ...
  • EpiPen® Jr and EpiPen® supply update
    November 23, 2017:  Mylan has advised that both EpiPen 300mcg and EpiPen Jr 150mcg adrenaline (epinephrine) autoinjectors have now been shipped to Australian pharmacy wholesalers and stock will become available to pharmacies shortly. The supply of no-charge EpiPen® Jr 150mcg, expiring 30 Novem...
  • Novalac Allergy Infant Formula Temporary Shortage
    November 14, 2017:  Bayer Australia Ltd (Bayer) has advised that they are experiencing a temporary shortage of Novalac Allergy rice protein based infant formula. This has resulted in very limited supply in pharmacies throughout Australia.  Bayer is working to increase the supply of ...
  • Supply of EpiPen® Jr with 30 November 2017 expiry during temporary shortage
    November 8, 2017:  Mylan Australia is experiencing a temporary shortage of EpiPen® Jr 150mcg adrenaline (epinephrine) autoinjectors. This supply disruption is due to an unforeseen delay in supply from the overseas manufacturer. In the meantime, to minimise the impact on patient care, Mylan has...
  • AusPollen App questionnaire
    October 20, 2017:  Auspollen invites people with hay fever (allergic rhinitis) and/or asthma that is made worse by allergens in the air, to evaluate free local AusPollen Apps.  The Apps provide daily levels of pollen in the air and can be accessed on the AusPollen website www.pollenforec...
  • ASCIA 2017 Conference Report
    September 19, 2017:   The 28th ASCIA Annual Conference was held in Auckland, New Zealand at the Viaduct Events Centre from Wednesday 13th to Friday 15th September 2017. This conference was a great success, with more than 550 registrations, an outstanding program, an interactive confe...
  • Food and Drug Administration (FDA) letter regarding EpiPen® adrenaline (epinephrine) autoinjectors
    September 9, 2017:  ASCIA has been alerted to a letter released by the FDA in the USA, regarding an investigation into the Mylan recall of EpiPen® devices earlier this year. To date, ASCIA has not received any correspondence regarding EpiPen®s failing to be discharged in an emergency situation...
  • ASCIA website update - Locate a Specialist
    September 5, 2017:  The ASCIA website listings for Allergy and Clinical Immunology Services in Australia and New Zealand have been significantly updated, to provide additional information in a more mobile/tablet responsive format.  The updated lists of Full (Ordinary) ASCIA members workin...
ASCIA is a WAO member society

ASCIA is a WAO member society
Follow ASCIA

ASCIA on facebookASCIA on TwitterASCIA on YouTube

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Disclaimer and Privacy

The ASCIA website is intended for use by ASCIA members, other health professionals, the general public and media. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors and Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites.

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.


This website is certified by Health On the Net Foundation. Click to verify.This site complies with the
HONcode standard for
trustworthy health

Verify here.